{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:42:51Z","timestamp":1790692971096,"version":"4.1.0"},"reference-count":134,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.cbpa.2009.04.615","type":"journal-article","created":{"date-parts":[[2009,6,4]],"date-time":"2009-06-04T05:00:51Z","timestamp":1244091651000},"page":"321-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["From endocannabinoid profiling to \u2018endocannabinoid therapeutics\u2019"],"prefix":"10.1016","volume":"13","author":[{"given":"Alessia","family":"Ligresti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Petrosino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Marzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbpa.2009.04.615_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ejlt.200800233","article-title":"Lipidomic methodologies applicable to the study of endocannabinoids and related compounds: endocannabinoidomics","volume":"111","author":"Bisogno","year":"2009","journal-title":"Eur J Lipid Sci Technol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib2","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.4049\/jimmunol.177.12.8796","article-title":"Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice","volume":"177","author":"Oka","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib3","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1126\/science.1142265","article-title":"Attenuation of allergic contact dermatitis through the endocannabinoid system","volume":"316","author":"Karsak","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.cbpa.2009.04.615_bib4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pain.2006.06.016","article-title":"Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain","volume":"126","author":"Mitrirattanakul","year":"2006","journal-title":"Pain"},{"key":"10.1016\/j.cbpa.2009.04.615_bib5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neuropharm.2006.08.011","article-title":"Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats","volume":"52","author":"Petrosino","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.cbpa.2009.04.615_bib6","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/35071088","article-title":"Leptin-regulated endocannabinoids are involved in maintaining food intake","volume":"410","author":"Di Marzo","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.cbpa.2009.04.615_bib7","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI200523057","article-title":"Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity","volume":"115","author":"Osei-Hyiaman","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cbpa.2009.04.615_bib8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1172\/JCI17725","article-title":"The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis","volume":"112","author":"Cota","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cbpa.2009.04.615_bib9","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1210\/jc.2005-2679","article-title":"Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia","volume":"91","author":"Matias","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cbpa.2009.04.615_bib10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/oby.2007.106","article-title":"Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet","volume":"16","author":"Starowicz","year":"2008","journal-title":"Obesity"},{"key":"10.1016\/j.cbpa.2009.04.615_bib11","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.2337\/diabetes.54.10.2838","article-title":"Activation of the peripheral endocannabinoid system in human obesity","volume":"54","author":"Engeli","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.cbpa.2009.04.615_bib12","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.2337\/db06-0812","article-title":"Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity","volume":"55","author":"Bl\u00fcher","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.cbpa.2009.04.615_bib13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/sj.ijo.0803539","article-title":"Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men","volume":"31","author":"C\u00f4t\u00e9","year":"2007","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.cbpa.2009.04.615_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2008.12.040","article-title":"Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis","author":"Montecucco","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cbpa.2009.04.615_bib15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.108.811992","article-title":"Activated endocannabinoid system in coronary artery","volume":"119","author":"Sugamura","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cbpa.2009.04.615_bib16","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/gut.2005.090472","article-title":"Endocannabinoid overactivity and intestinal inflammation","volume":"55","author":"Di Marzo","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.cbpa.2009.04.615_bib17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1096\/fj.05-4943fje","article-title":"Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation","volume":"20","author":"D\u2019Argenio","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.cbpa.2009.04.615_bib18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00109-007-0192-3","article-title":"Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats","volume":"85","author":"D\u2019Argenio","year":"2007","journal-title":"J Mol Med"},{"key":"10.1016\/j.cbpa.2009.04.615_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1478-3231.2006.01401.x","article-title":"Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease","volume":"27","author":"Mendez-Sanchez","year":"2007","journal-title":"Liver Int"},{"key":"10.1016\/j.cbpa.2009.04.615_bib20","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/j.gastro.2004.12.050","article-title":"Antifibrogenic role of the cannabinoid receptor CB2 in the liver","volume":"128","author":"Julien","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cbpa.2009.04.615_bib21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nm1421","article-title":"CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis","volume":"12","author":"Teixeira-Clerc","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.cbpa.2009.04.615_bib22","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1096\/fj.06-7451com","article-title":"Cannabinoid-2 receptor mediates protection against hepatic ischemia\/reperfusion injury","volume":"21","author":"B\u00e1tkai","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.cbpa.2009.04.615_bib23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1088208","article-title":"CB1 cannabinoid receptors and on-demand defense against excitotoxicity","volume":"302","author":"Marsicano","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.cbpa.2009.04.615_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.nbd.2006.04.010","article-title":"Protective activation of the endocannabinoid system during ischemia in dopamine neurons","volume":"24","author":"Melis","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.cbpa.2009.04.615_bib25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/35097089","article-title":"An endogenous cannabinoid (2-AG) is neuroprotective after brain injury","volume":"413","author":"Panikashvili","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.cbpa.2009.04.615_bib26","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1523\/JNEUROSCI.22-16-06900.2002","article-title":"Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission","volume":"22","author":"Gubellini","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.cbpa.2009.04.615_bib27","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1096\/fj.04-3010fje","article-title":"A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease","volume":"19","author":"van der Stelt","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.cbpa.2009.04.615_bib28","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1046\/j.1460-9568.2003.02896.x","article-title":"Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias","volume":"18","author":"Ferrer","year":"2003","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.cbpa.2009.04.615_bib29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.phrs.2007.09.002","article-title":"Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders","volume":"56","author":"Bisogno","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cbpa.2009.04.615_bib30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/ana.20462","article-title":"High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients","volume":"57","author":"Pisani","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.neuint.2007.06.031","article-title":"Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6\/2 mice, a transgenic model of Huntington's disease","volume":"52","author":"Bisogno","year":"2008","journal-title":"Neurochem Int"},{"key":"10.1016\/j.cbpa.2009.04.615_bib32","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1007\/s00018-006-6037-3","article-title":"Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels","volume":"63","author":"van der Stelt","year":"2006","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.cbpa.2009.04.615_bib33","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1523\/JNEUROSCI.23-35-11136.2003","article-title":"Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains","volume":"23","author":"Benito","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.cbpa.2009.04.615_bib34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.nbd.2005.03.002","article-title":"Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and\/or vanilloid receptors in a rat model of multiple sclerosis","volume":"20","author":"Cabranes","year":"2005","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.cbpa.2009.04.615_bib35","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1073\/pnas.0510418103","article-title":"Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection","volume":"103","author":"Witting","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cbpa.2009.04.615_bib36","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1093\/brain\/awm160","article-title":"The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis","volume":"130","author":"Centonze","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.cbpa.2009.04.615_bib37","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm1561","article-title":"Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells","volume":"13","author":"Maresz","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.cbpa.2009.04.615_bib38","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2174\/138161208785740072","article-title":"The endocannabinoid system in Parkinson's disease","volume":"14","author":"Di Filippo","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.cbpa.2009.04.615_bib39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neuron.2005.11.027","article-title":"The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells","volume":"49","author":"Eljaschewitsch","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.cbpa.2009.04.615_bib40","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1210\/en.2004-0638","article-title":"Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis","volume":"145","author":"Patel","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.cbpa.2009.04.615_bib41","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.1523\/JNEUROSCI.0153-06.2006","article-title":"Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes","volume":"26","author":"Kamprath","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.cbpa.2009.04.615_bib42","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/nature03658","article-title":"An endocannabinoid mechanism for stress-induced analgesia","volume":"435","author":"Hohmann","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.cbpa.2009.04.615_bib43","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1089\/jpm.2006.9.802","article-title":"Cannabinoids in the treatment of symptoms in cancer and AIDS","volume":"9","author":"Wilner","year":"2006","journal-title":"J Palliat Med"},{"key":"10.1016\/j.cbpa.2009.04.615_bib44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/bmj.323.7303.16","article-title":"Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review","volume":"323","author":"Tram\u00e8r","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.cbpa.2009.04.615_bib45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1517\/13543784.17.1.85","article-title":"Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain","volume":"17","author":"Davis","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.cbpa.2009.04.615_bib46","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/gast.2001.28466","article-title":"Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret","volume":"121","author":"Van Sickle","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cbpa.2009.04.615_bib47","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00213-007-0970-1","article-title":"The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat","volume":"196","author":"Rock","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.cbpa.2009.04.615_bib48","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1111\/j.1460-9568.2007.05521.x","article-title":"Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret","volume":"25","author":"Sharkey","year":"2007","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.cbpa.2009.04.615_bib49","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1155\/2008\/725702","article-title":"Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus","volume":"22","author":"Costiniuk","year":"2008","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib50","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/sj.bjp.0707313","article-title":"Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus","volume":"151","author":"Soria-G\u00f3mez","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib51","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1007\/s00125-008-1048-2","article-title":"The endocannabinoid system in obesity and type 2 diabetes","volume":"51","author":"Di Marzo","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.cbpa.2009.04.615_bib52","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/138161209787315666","article-title":"Pleiotropic effects of rimonabant: clinical implications","volume":"15","author":"Despr\u00e9s","year":"2009","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.cbpa.2009.04.615_bib53","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1476-5381.2008.00107.x","article-title":"Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice","volume":"156","author":"Riedel","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib54","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cmet.2007.11.012","article-title":"The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake","volume":"7","author":"Addy","year":"2008","journal-title":"Cell Metab"},{"key":"10.1016\/j.cbpa.2009.04.615_bib55","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1021\/jm8012932","article-title":"Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist","volume":"52","author":"Griffith","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2009.04.615_bib56","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.299.13.1547","article-title":"Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.cbpa.2009.04.615_bib57","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/ATVBAHA.108.168757","article-title":"Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice","volume":"29","author":"Dol-Gleizes","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib58","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/ATVBAHA.108.176362","article-title":"Effect of rimonabant on the high-triglyceride\/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial","volume":"29","author":"Despr\u00e9s","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib59","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1517\/14656566.9.7.1189","article-title":"Managing neuropathic pain with Sativex: a review of its pros and cons","volume":"9","author":"Perez","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cbpa.2009.04.615_bib60","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.bjp.0707531","article-title":"Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain","volume":"153","author":"Guindon","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib61","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.lfs.2004.04.010","article-title":"Ajulemic acid: a novel cannabinoid produces analgesia without a \u201chigh\u201d","volume":"75","author":"Burstein","year":"2004","journal-title":"Life Sci"},{"key":"10.1016\/j.cbpa.2009.04.615_bib62","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/sj.bjp.0706510","article-title":"Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models","volume":"147","author":"Jayamanne","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib63","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/sj.bjp.0707145","article-title":"Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors","volume":"150","author":"Maione","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib64","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1124\/jpet.107.119941","article-title":"The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3\u2032-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice","volume":"322","author":"Russo","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cbpa.2009.04.615_bib65","first-page":"1297","article-title":"Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain","volume":"155","author":"Sagar","year":"2008","journal-title":"J Pharmacol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib66","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/sj.bjp.0707425","article-title":"The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation","volume":"152","author":"Comelli","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib67","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bbalip.2008.10.007","article-title":"Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo","volume":"1791","author":"Bisogno","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cbpa.2009.04.615_bib68","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nchembio.129","article-title":"Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects","volume":"5","author":"Long","year":"2009","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib69","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1124\/jpet.108.141382","article-title":"N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase","volume":"327","author":"Burston","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cbpa.2009.04.615_bib70","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1476-5381.2008.00029.x","article-title":"The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1","volume":"156","author":"Fowler","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib71","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1136\/gut.2008.148791","article-title":"Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects","volume":"57","author":"Izzo","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.cbpa.2009.04.615_bib72","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0016-5085(03)00892-8","article-title":"An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice","volume":"125","author":"Izzo","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cbpa.2009.04.615_bib73","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-2036.1999.00441.x","article-title":"Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study","volume":"13","author":"McCallum","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cbpa.2009.04.615_bib74","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2982.2006.00834.x","article-title":"Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study","volume":"18","author":"Esfandyari","year":"2006","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cbpa.2009.04.615_bib75","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/j.gastro.2005.06.018","article-title":"Fatty acid amide hydrolase controls mouse intestinal motility in vivo","volume":"129","author":"Capasso","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cbpa.2009.04.615_bib76","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/sj.bjp.0707682","article-title":"The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet","volume":"153","author":"Di Marzo","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib77","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00109-008-0359-6","article-title":"Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors","volume":"86","author":"Storr","year":"2008","journal-title":"J Mol Med"},{"key":"10.1016\/j.cbpa.2009.04.615_bib78","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2826.2008.01679.x","article-title":"The endocannabinoid system and liver diseases","volume":"20","author":"Caraceni","year":"2008","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib79","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S1262-3636(08)74604-4","article-title":"Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis","volume":"34","author":"Mallat","year":"2008","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.cbpa.2009.04.615_bib80","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1124\/jpet.107.131896","article-title":"Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats","volume":"324","author":"Mu\u00f1oz-Luque","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cbpa.2009.04.615_bib81","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.01.004","article-title":"Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis","author":"Domenicali","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cbpa.2009.04.615_bib82","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.bjp.0706331","article-title":"Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats","volume":"146","author":"Gaskari","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib83","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1124\/jpet.107.120147","article-title":"Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage","volume":"322","author":"Karanian","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cbpa.2009.04.615_bib84","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/jpet.103.051920","article-title":"The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy","volume":"307","author":"Wallace","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cbpa.2009.04.615_bib85","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1523\/JNEUROSCI.3966-06.2007","article-title":"Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures","volume":"27","author":"Chen","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.cbpa.2009.04.615_bib86","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1161\/01.STR.0000079817.68944.1E","article-title":"Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210","volume":"34","author":"Leker","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.cbpa.2009.04.615_bib87","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.neuroscience.2008.01.022","article-title":"Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic\/reperfusion injury","volume":"152","author":"Zhang","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.cbpa.2009.04.615_bib88","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1124\/mol.66.2.204","article-title":"Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice","volume":"66","author":"Jin","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib89","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.2174\/138161208785740054","article-title":"Role of cannabinoids and endocannabinoids in cerebral ischemia","volume":"14","author":"Hillard","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.cbpa.2009.04.615_bib90","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1523\/JNEUROSCI.3101-05.2006","article-title":"The endocannabinoid system promotes astroglial differentiation by acting on neural progenitor cells","volume":"26","author":"Aguado","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.cbpa.2009.04.615_bib91","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.jcbfm.9600447","article-title":"Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia\/reperfusion model","volume":"27","author":"Zhang","year":"2007","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.cbpa.2009.04.615_bib92","doi-asserted-by":"crossref","DOI":"10.1007\/s11481-009-9148-4","article-title":"Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke","author":"Zhang","year":"2009","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib93","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.nbd.2005.11.004","article-title":"The endocannabinoid 2-AG protects the blood\u2013brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines","volume":"22","author":"Panikashvili","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.cbpa.2009.04.615_bib94","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1476-5381.2008.00088.x","article-title":"The endocannabinoid system as a target for the treatment of motor dysfunction","volume":"156","author":"Fern\u00e1ndez-Ruiz","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib95","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/mds.10312","article-title":"Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease","volume":"18","author":"Segovia","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.cbpa.2009.04.615_bib96","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.expneurol.2007.07.021","article-title":"Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors","volume":"208","author":"Morgese","year":"2007","journal-title":"Exp Neurol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib97","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.neuropharm.2006.04.016","article-title":"A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and l-DOPA induced locomotion in normal and reserpine-treated rats","volume":"51","author":"Lee","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.cbpa.2009.04.615_bib98","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.brainres.2006.11.063","article-title":"Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties","volume":"1134","author":"Garc\u00eda-Arencibia","year":"2007","journal-title":"Brain Res"},{"key":"10.1016\/j.cbpa.2009.04.615_bib99","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/sj.npp.1300407","article-title":"Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function","volume":"29","author":"Fernandez-Espejo","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.cbpa.2009.04.615_bib100","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.nbd.2004.10.015","article-title":"Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism","volume":"18","author":"Fernandez-Espejo","year":"2005","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.cbpa.2009.04.615_bib101","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neulet.2008.04.041","article-title":"Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats","volume":"438","author":"Garc\u00eda-Arencibia","year":"2008","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.cbpa.2009.04.615_bib102","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00002826-200405000-00003","article-title":"Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease","volume":"27","author":"Mesnage","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib103","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.WNL.0000140288.48796.8E","article-title":"Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study","volume":"63","author":"Carroll","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.cbpa.2009.04.615_bib104","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","article-title":"Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study","volume":"57","author":"Sieradzan","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.cbpa.2009.04.615_bib105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/mds.1280","article-title":"Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia","volume":"17","author":"Fox","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.cbpa.2009.04.615_bib106","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1046\/j.1471-4159.2003.01595.x","article-title":"Compounds acting at the endocannabinoid and\/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease","volume":"84","author":"Lastres-Becker","year":"2003","journal-title":"J Neurochem"},{"key":"10.1016\/j.cbpa.2009.04.615_bib107","article-title":"Cannabinoid CB(2) receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease","author":"Sagredo","year":"2008","journal-title":"Glia"},{"key":"10.1016\/j.cbpa.2009.04.615_bib108","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1460-9568.2007.05717.x","article-title":"Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors","volume":"26","author":"Sagredo","year":"2007","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.cbpa.2009.04.615_bib109","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejphar.2003.08.026","article-title":"Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade","volume":"477","author":"Mazzola","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib110","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","article-title":"Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation","volume":"25","author":"Ram\u00edrez","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.cbpa.2009.04.615_bib111","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1124\/jpet.107.121566","article-title":"Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence","volume":"322","author":"Esposito","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cbpa.2009.04.615_bib112","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.2174\/138161208785740036","article-title":"The endocannabinoid system and multiple sclerosis","volume":"14","author":"Baker","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.cbpa.2009.04.615_bib113","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/jnnp.2005.070136","article-title":"Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up","volume":"76","author":"Zajicek","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cbpa.2009.04.615_bib114","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00415-006-0218-8","article-title":"Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial","volume":"253","author":"Wissel","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib115","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1468-1331.2006.01639.x","article-title":"Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis","volume":"14","author":"Collin","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib116","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/sj.npp.1300655","article-title":"Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear","volume":"30","author":"Chhatwal","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.cbpa.2009.04.615_bib117","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00213-006-0514-0","article-title":"The cannabinoid receptor agonist WIN 55,212-2 facilitates the extinction of contextual fear memory and spatial memory in rats","volume":"188","author":"Pamplona","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.cbpa.2009.04.615_bib118","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nm803","article-title":"Modulation of anxiety through blockade of anandamide hydrolysis","volume":"9","author":"Kathuria","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.cbpa.2009.04.615_bib119","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1124\/jpet.106.101287","article-title":"Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling","volume":"318","author":"Patel","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cbpa.2009.04.615_bib120","doi-asserted-by":"crossref","first-page":"18620","DOI":"10.1073\/pnas.0509591102","article-title":"Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis","volume":"102","author":"Gobbi","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cbpa.2009.04.615_bib121","doi-asserted-by":"crossref","first-page":"11700","DOI":"10.1523\/JNEUROSCI.1636-07.2007","article-title":"Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex","volume":"27","author":"Bambico","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.cbpa.2009.04.615_bib122","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/cercor\/bhm161","article-title":"Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex","volume":"18","author":"Rubino","year":"2008","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.cbpa.2009.04.615_bib123","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/npp.2008.98","article-title":"Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels","volume":"34","author":"Micale","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.cbpa.2009.04.615_bib124","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1755-5949.2008.00071.x","article-title":"The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD)","volume":"15","author":"Fraser","year":"2009","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.cbpa.2009.04.615_bib125","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/nrd2775","article-title":"End of the line for cannabinoid receptor 1 as an anti-obesity target?","volume":"7","author":"Jones","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cbpa.2009.04.615_bib126","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.coph.2008.12.001","article-title":"Endocannabinoid signals in the control of emotion","volume":"9","author":"Lutz","year":"2009","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib127","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nature05488","article-title":"Abdominal obesity and metabolic syndrome","volume":"444","author":"Despr\u00e9s","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.cbpa.2009.04.615_bib128","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/oby.2008.647","article-title":"Changes in symptoms of depression with weight loss: results of a randomized trial","volume":"17","author":"Faulconbridge","year":"2009","journal-title":"Obesity"},{"key":"10.1016\/j.cbpa.2009.04.615_bib129","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/ncpcardio1319","article-title":"Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?","volume":"5","author":"Di Marzo","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.cbpa.2009.04.615_bib130","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.1021\/jm070678q","article-title":"New N-arachidonoylserotonin analogues with potential \u201cdual\u201d mechanism of action against pain","volume":"50","author":"Ortar","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2009.04.615_bib131","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejphar.2007.02.051","article-title":"Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin","volume":"565","author":"Holt","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cbpa.2009.04.615_bib132","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.neuropharm.2005.12.002","article-title":"Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain","volume":"50","author":"Guindon","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.cbpa.2009.04.615_bib133","doi-asserted-by":"crossref","first-page":"31405","DOI":"10.1074\/jbc.M501489200","article-title":"Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system","volume":"280","author":"H\u00f6gest\u00e4tt","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cbpa.2009.04.615_bib134","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejphar.2005.12.015","article-title":"The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors","volume":"531","author":"Ottani","year":"2006","journal-title":"Eur J Pharmacol"}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136759310900060X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136759310900060X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:24:43Z","timestamp":1761272683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S136759310900060X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":134,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S136759310900060X"],"URL":"https:\/\/doi.org\/10.1016\/j.cbpa.2009.04.615","relation":{},"ISSN":["1367-5931"],"issn-type":[{"value":"1367-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From endocannabinoid profiling to \u2018endocannabinoid therapeutics\u2019","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbpa.2009.04.615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}